JAMIE FAUST: Open Payments
NPI 1710521422 · SHENANDOAH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,058 in 34 payments from 14 companies in 2025. Trend: 2023 $145 · 2024 $462 · 2025 $1,058
Food & beverage: $1,058
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 7 | $221 |
| Ardelyx, Inc. | 4 | $183 |
| KYOWA KIRIN, INC. | 4 | $176 |
| Novartis Pharmaceuticals Corporation | 1 | $89 |
| SCPHARMACEUTICALS INC. | 3 | $60 |
| Lilly USA, LLC | 3 | $52 |
| Amgen Inc. | 2 | $51 |
| AstraZeneca Pharmaceuticals LP | 2 | $46 |
| AKEBIA THERAPEUTICS INC | 2 | $41 |
| Renalytix AI, Inc. | 2 | $39 |
Products named: TARPEYO, CRYSVITA, XPHOZAH 30 MG, Vanrafia, IBSRELA, FUROSCIX, KRYSTEXXA, Vafseo.
Industry payments across TX — which companies pay providers there.
